Immunome Can Take The Fight To Competitors With Varegacestat
Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why I remain bullish on IMNM stock.
NIO: This Stock Isn't Going Anywhere
We warn of NIO's profitability challenges and reliance on external financing, making it a risky long-term investment. Read an investment analysis of NIO stock here.
Stock market today: Wall Street edges lower after the Fed opts to keep interest rates steady
U.S. stocks are edging lower after the Federal Reserve opted not to cut interest rates for the first time since it began ...